HOOK - HOOKIPA Pharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

HOOKIPA Pharma Inc.

350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States


Full Time Employees56

Key Executives

NameTitlePayExercisedYear Born
Mr. Joern AldagChief Exec. Officer574.31kN/A1959
Dr. Reinhard KanderaChief Financial Officer407.36kN/A1969
Dr. Igor Matushansky M.D., Ph.D.Chief Medical Officer and Global Head of R&D526.72kN/A1973
Mr. Daniel PinschewerCo-Founder & Chief Scientific OfficerN/AN/A1975
Prof. Rolf M. Zinkernagel Ph.D., M.D.Co-FounderN/AN/A1944
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Corporate Governance

HOOKIPA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.